While Axsome Therapeutics Inc has overperformed by 4.03%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AXSM rose by 38.17%, with highs and lows ranging from $132.25 to $64.11, whereas the simple moving average jumped by 50.63% in the last 200 days.
On February 11, 2025, Deutsche Bank started tracking Axsome Therapeutics Inc (NASDAQ: AXSM) recommending Buy. A report published by Mizuho on December 31, 2024, Reiterated its previous ‘Outperform’ rating for AXSM. Wells Fargo also rated AXSM shares as ‘Overweight’, setting a target price of $140 on the company’s shares in an initiating report dated September 03, 2024. BofA Securities August 06, 2024d the rating to Buy on August 06, 2024, and set its price target from $95 to $106. Needham initiated its ‘Buy’ rating for AXSM, as published in its report on July 22, 2024. Morgan Stanley’s report from April 29, 2024 suggests a price prediction of $115 for AXSM shares, giving the stock a ‘Overweight’ rating. Robert W. Baird also rated the stock as ‘Outperform’.
Analysis of Axsome Therapeutics Inc (AXSM)
Further, the quarter-over-quarter increase in sales is 81.27%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Axsome Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -171.61% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.37, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 858.72K can be a very valuable indicator of volatility for AXSM stock. On a monthly basis, the volatility of the stock is set at 5.42%, whereas on a weekly basis, it is put at 5.68%, with a gain of 17.07% over the past seven days. Furthermore, long-term investors anticipate a median target price of $152.35, showing growth from the present price of $132.20, which can serve as yet another indication of whether AXSM is worth investing in or should be passed over.
How Do You Analyze Axsome Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 18.64%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 81.72% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AXSM shares are owned by institutional investors to the tune of 81.72% at present.
